SEC filings
Abbott Laboratories (ABT)
Recent filings Abbott Laboratories made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000001800All filings on SEC.gov
10-QQuarterly report
Quarterly report
Abbott Laboratories reported third-quarter 2026 net sales of $13.0 billion, up 14.5% from a year earlier (14.8% excluding foreign exchange), driven by its acquisition of Exact Sciences and growth in Medical Devices and Established…
8-KCurrent report
Other Events
Abbott Laboratories announced its intention to separate its global Nutrition business into an independent, publicly traded company via a tax-free share distribution to Abbott shareholders, expected to be completed by the end of 2027…
8-KCurrent report
Results of Operations and Financial Condition
Abbott Laboratories reported third-quarter 2026 sales growth of 14.5% on a reported basis and 7.0% on a comparable basis, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, and reaffirmed the midpoint of its full-year 2026…
8-KCurrent report
Regulation FD Disclosure; Other Events
Abbott Laboratories has agreed to pay approximately $670 million to settle the Gill preterm-infant-formula lawsuit and necrotizing enterocolitis (NEC) claims brought on behalf of about 2,000 additional infants, after the Missouri Court of…
10-QQuarterly report
Quarterly report
Abbott Laboratories reported second-quarter 2026 net sales of $12.59 billion, up 13.0% from a year earlier, as its March 23, 2026 acquisition of Exact Sciences for about $20.6 billion lifted Diagnostic Products sales 42.3% and offset a…
8-KCurrent report
Results of Operations and Financial Condition
Abbott Laboratories reported second-quarter 2026 sales growth of 13.0 percent on a reported basis and 4.8 percent on a comparable basis, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, and raised its full-year 2026…
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Abbott Laboratories in Readster
Add Abbott Laboratories to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.